The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease
- PMID: 20108371
- DOI: 10.1002/mds.22748
The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease
Abstract
Cognitive dysfunction is one of the hallmarks of Huntington's disease (HD) and may precede the onset of motor symptoms. The Montreal Cognitive Assessment (MoCA), a brief cognitive screening instrument with high specificity and sensitivity for detecting early cognitive impairments, has not been studied in the HD population. In this study, we compare the MoCA with the mini-mental state examination (MMSE) as a screening tool for cognitive dysfunction among 53 patients with HD. The mean MMSE score was 26 +/- 2.4, and mean MoCA score was 21 +/- 4.4. Twenty-one patients (81%) of those who scored >or=26 on the MMSE had the MoCA score <26. Thirty-two patients (78%) of those who scored >or=24 on the MMSE had the MoCA score <24. The MoCA may be a more sensitive screening tool for cognitive impairments in HD relative to the MMSE.
(c) 2010 Movement Disorder Society.
Similar articles
-
A comparison of two brief screening measures of cognitive impairment in Huntington's disease.Mov Disord. 2010 Oct 15;25(13):2229-33. doi: 10.1002/mds.23181. Mov Disord. 2010. PMID: 20721924
-
Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease.Appl Neuropsychol Adult. 2013;20(1):33-40. doi: 10.1080/09084282.2012.670158. Epub 2012 Oct 9. Appl Neuropsychol Adult. 2013. PMID: 23373682
-
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.Mov Disord. 2008 Jan 30;23(2):297-9. doi: 10.1002/mds.21837. Mov Disord. 2008. PMID: 18044697
-
[The mini-mental state examination in screening of cognitive dysfunction and dementia].Ugeskr Laeger. 1998 Dec 7;160(50):7251-4. Ugeskr Laeger. 1998. PMID: 9859723 Review. Danish.
-
Montreal cognitive assessment for evaluating cognitive impairment in Huntington's disease: a systematic review.CNS Spectr. 2022 Feb;27(1):27-45. doi: 10.1017/S1092852920001868. Epub 2020 Oct 7. CNS Spectr. 2022. PMID: 33023702
Cited by
-
Which part of the Quick mild cognitive impairment screen (Qmci) discriminates between normal cognition, mild cognitive impairment and dementia?Age Ageing. 2013 May;42(3):324-30. doi: 10.1093/ageing/aft044. Age Ageing. 2013. PMID: 23612864 Free PMC article.
-
Validity of the Montreal Cognitive Assessment and the HIV Dementia Scale in the assessment of cognitive impairment in HIV-1 infected patients.J Neurovirol. 2015 Aug;21(4):383-90. doi: 10.1007/s13365-015-0324-4. Epub 2015 Feb 13. J Neurovirol. 2015. PMID: 25678141 Free PMC article.
-
Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease.Mov Disord. 2013 Oct;28(12):1744-7. doi: 10.1002/mds.25578. Epub 2013 Jun 24. Mov Disord. 2013. PMID: 23798501 Free PMC article.
-
Validation of Neuropsychological Tests to Screen for Dementia in Chinese Patients With Parkinson's Disease.Am J Alzheimers Dis Other Demen. 2016 Jun;31(4):368-74. doi: 10.1177/1533317515619478. Epub 2015 Dec 8. Am J Alzheimers Dis Other Demen. 2016. PMID: 26646116 Free PMC article.
-
Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study.Tremor Other Hyperkinet Mov (N Y). 2012;2:tre-02-86-476-4. doi: 10.7916/D8DN43SC. Epub 2012 Aug 6. Tremor Other Hyperkinet Mov (N Y). 2012. PMID: 23439575 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical